MCID: ATT013
MIFTS: 66

Attention Deficit-Hyperactivity Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder

MalaCards integrated aliases for Attention Deficit-Hyperactivity Disorder:

Name: Attention Deficit-Hyperactivity Disorder 57 54 40
Attention Deficit Hyperactivity Disorder 41 12 76 37 29 6 43 15 63 73
Adhd 57 41 12 3
Attention Deficit-Hyperactivity Disorder, Susceptibility to 57 13 6
Attention Deficit Disorder 12 55 73
Attention-Deficit/hyperactivity Disorder, Predominantly Inattentive Type 73
Attention Deficit Disorder with Hyperactivity 44
Attention-Deficit Hyperactivity Disorder 55
Hyperactivity of Childhood 57
Hyperkinetic Disorder 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
attention deficit-hyperactivity disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 143465
Disease Ontology 12 DOID:1094
ICD9CM 35 314.8
MeSH 44 D001289
NCIt 50 C35092
MedGen 42 C1263846
KEGG 37 H01895
ICD10 33 F90 F90.0 F90.9

Summaries for Attention Deficit-Hyperactivity Disorder

PubMed Health : 63 About attention deficit hyperactivity disorder: Attention deficit hyperactivity disorder, ADHD, is a mental disorder in which children are especially inattentive, impulsive or hyperactive. “Inattentive” refers to children who have difficulties focusing and are easily distracted. Overly “impulsive” children act in a way that is extremely rash, inconsiderate, careless or impatient for their age. “Hyperactive” describes children who are restless or constantly fidgeting – for instance, they may not be able to sit still during school lessons, and get up and walk around the classroom a lot instead.Severe ADHD can cause major problems in the life and everyday routine of both the child and their parents and brothers and sisters: Because children with ADHD behave differently than expected, they often cause trouble. They need a lot of attention. They find it more difficult to learn because of their short attention span. ADHD may also be accompanied by other kinds of mental disorders.The number of children being diagnosed with ADHD has increased in recent years. Some people are wary of this development and doubt that ADHD is really that common. They are worried that a lot of children who are diagnosed with ADHD are simply a little overactive, but otherwise healthy. A wrong diagnosis may lead to unnecessary treatment. Being wrongly labelled as mentally ill may also affect a child’s self-esteem.But there are also children and teenagers who actually have ADHD but are not diagnosed with it. This can also have a negative effect, because they may not get treatment that could help them. So it is very important to take the time to look into things so ADHD can be ruled out or diagnosed.

MalaCards based summary : Attention Deficit-Hyperactivity Disorder, also known as attention deficit hyperactivity disorder, is related to gilles de la tourette syndrome and conduct disorder, and has symptoms including back pain, headache and pain. An important gene associated with Attention Deficit-Hyperactivity Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Dopaminergic synapse and Serotonergic synapse. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and thyroid, and related phenotypes are hyperactivity and attention deficit hyperactivity disorder

MedlinePlus : 43 Is it hard for your child to sit still? Does your child act without thinking first? Does your child start but not finish things? If so, your child may have attention deficit hyperactivity disorder (ADHD). Nearly everyone shows some of these behaviors at times, but ADHD lasts more than 6 months and causes problems in school, at home and in social situations. ADHD is more common in boys than girls. It affects 3-5 percent of all American children. The main features of ADHD are Inattention Hyperactivity Impulsivity No one knows exactly what causes ADHD. It sometimes runs in families, so genetics may be a factor. There may also be environmental factors. A complete evaluation by a trained professional is the only way to know for sure if your child has ADHD. Treatment may include medicine to control symptoms, therapy, or both. Structure at home and at school is important. Parent training may also help. NIH: National Institute of Mental Health

CDC : 3 People with ADHD may have trouble paying attention, controlling impulsive behaviors (may act without thinking about what the result will be), or be overly active. Although ADHD can’t be cured, it can be successfully managed and some symptoms may improve as the child ages.

NINDS : 54 Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.

Disease Ontology : 12 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone\

Wikipedia : 76 Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It... more...

Description from OMIM: 143465

Related Diseases for Attention Deficit-Hyperactivity Disorder

Diseases in the Attention Deficit-Hyperactivity Disorder family:

Attention Deficit-Hyperactivity Disorder 1 Attention Deficit-Hyperactivity Disorder 2
Attention Deficit-Hyperactivity Disorder 3 Attention Deficit-Hyperactivity Disorder 4

Diseases related to Attention Deficit-Hyperactivity Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 gilles de la tourette syndrome 34.3 ADRA2A COMT DRD4 DRD5 SLC6A3
2 conduct disorder 33.3 COMT DRD4 DRD5 SLC6A3
3 oppositional defiant disorder 33.2 COMT DRD4 SLC6A2 SLC6A3 TPH2
4 autism 33.2 COMT DRD4 MECP2 SLC6A3 SLC9A9 TPH2
5 tic disorder 33.1 DRD4 DRD5 SLC6A3 TPH2
6 personality disorder 32.9 COMT DRD4 SLC6A3 TPH2
7 bipolar disorder 32.8 COMT DRD4 DRD5 SLC6A3 TPH2
8 obsessive-compulsive disorder 32.7 COMT DRD4 SLC6A3 TPH2
9 schizophrenia 32.6 COMT DRD4 DRD5 MECP2 SLC6A2 SLC6A3
10 substance abuse 32.6 COMT DRD4 DRD5 SLC6A3
11 anxiety 32.6 COMT SLC6A2 TPH2
12 mood disorder 32.5 COMT DRD4 SLC6A2 TPH2
13 major depressive disorder 32.4 COMT DRD4 SLC6A2 SLC6A3 TPH2
14 disease of mental health 32.3 COMT DRD4 MECP2 SLC6A2 SLC6A3
15 alcohol dependence 32.3 COMT DRD4 SLC6A3 TPH2
16 substance dependence 32.2 DRD4 DRD5 SLC6A3
17 psychotic disorder 31.5 COMT DRD4 SLC6A3
18 panic disorder 31.3 COMT SLC6A2 TPH2
19 alacrima, achalasia, and mental retardation syndrome 31.2 C12orf57 MECP2 VPS13B
20 premature ejaculation 31.2 COMT SLC6A3
21 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.7
22 attention deficit-hyperactivity disorder 1 12.5
23 attention deficit-hyperactivity disorder 2 12.5
24 attention deficit-hyperactivity disorder 4 12.5
25 attention deficit-hyperactivity disorder 3 12.5
26 aarskog-scott syndrome 11.7
27 learning disability 11.5
28 asperger syndrome 11.5
29 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.4
30 pol iii-related leukodystrophies 11.4
31 specific developmental disorder 11.3 COMT DRD4 DRD5 MECP2 SLC6A2 SLC6A3
32 major affective disorder 1 11.2 SLC6A3 TPH2
33 migraine with or without aura 1 11.2 COMT DRD4 DRD5 SLC6A3
34 mental depression 11.2 COMT SLC6A2 TPH2
35 thyroid hormone resistance, generalized, autosomal dominant 11.1
36 epilepsy, focal, with speech disorder and with or without mental retardation 11.1
37 cerebral creatine deficiency syndrome 1 11.1
38 legius syndrome 11.1
39 chromosome 1q21.1 deletion syndrome, 1.35-mb 11.1
40 chromosome 16p11.2 deletion syndrome, 220-kb 11.1
41 chromosome 15q11.2 deletion syndrome 11.1
42 intellectual developmental disorder with gastrointestinal difficulties and high pain threshold 11.1
43 impulse control disorder 11.1
44 15q13.3 microduplication syndrome 11.1
45 16p13.11 microduplication syndrome 11.1
46 bain type of x-linked syndromic intellectual disability 11.1
47 chromosome 17q11.2 deletion syndrome 11.1
48 xp22.3 microdeletion syndrome 11.1
49 aging 10.8
50 basal ganglia disease 10.8

Graphical network of the top 20 diseases related to Attention Deficit-Hyperactivity Disorder:



Diseases related to Attention Deficit-Hyperactivity Disorder

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder

Symptoms via clinical synopsis from OMIM:

57
Neuro:
hyperactivity

Misc:
male:female ratio 8:1


Clinical features from OMIM:

143465

Human phenotypes related to Attention Deficit-Hyperactivity Disorder:

32
# Description HPO Frequency HPO Source Accession
1 hyperactivity 32 HP:0000752
2 attention deficit hyperactivity disorder 32 HP:0007018

UMLS symptoms related to Attention Deficit-Hyperactivity Disorder:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Attention Deficit-Hyperactivity Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 ADRA2A COMT DOCK3 DRD4 DRD5 GNB5
2 nervous system MP:0003631 9.36 CDK20 COMT DOCK3 DRD4 DRD5 GNB5

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder

PubMedHealth treatment related to Attention Deficit-Hyperactivity Disorder: 63

Before any treatment is started, the doctor will talk about what ADHD is and how everyone can best cope with it. As well as the parents and their child, teachers and preschool teachers may also be there too. It may then turn out that there is no urgent need for treatment. When deciding whether or not treatment is necessary, it is important to consider how much of a problem the behavior is for the child and their parents, and whether things like their performance at school are suffering as a result.If a child only has a mild form of ADHD that does not affect his or her life too much, it might be enough to complete a parent training and education program on dealing with ADHD. These programs can be taken as a class with an instructor or done on your own using written material.If a child has moderate or severe ADHD that is causing problems at school and in their social environment, it may be helpful to try interventions at school or have family or behavioral therapy. The type of help that will be most effective will depend on the child’s age, whether they tend to be more inattentive or more hyperactive, and what areas of their life the ADHD has the greatest impact on.Medication can relieve ADHD symptoms. It is mainly considered for the treatment of more severe ADHD when psychological and educational approaches are not effective enough. Medicine containing the drug methylphenidate is the most commonly used medication. If methylphenidate does not work or cannot be used for other reasons, the drugs atomoxetine, dexamfetamine or lisdexamfetamine may be used instead.Treatment at a psychosomatic or psychiatric hospital for children and teenagers may be a good idea for children who are extremely hyperactive and impulsive and have great difficulty coping in daily life, or can no longer cope at all. Hospital treatment may also be needed if the child has other severe mental disorders too.

Drugs for Attention Deficit-Hyperactivity Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 335)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
4
Dextroamphetamine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-64-9 5826
5
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
6
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
7
Clonidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 4205-90-7 2803
8
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
9
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
10
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
11
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
12
Sertraline Approved Phase 4 79617-96-2 68617
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
15 Piracetam Approved, Investigational Phase 4 7491-74-9
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
17
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
18
Methamphetamine Approved, Illicit Phase 4,Phase 2,Not Applicable 537-46-2 10836
19
Menthol Approved Phase 4,Phase 2,Not Applicable 2216-51-5 16666
20
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
21
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 300-62-9 5826 3007
22
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29110-47-2 3519
23
Galantamine Approved Phase 4 357-70-0 9651
24
Bupropion Approved Phase 4,Phase 3,Phase 2,Not Applicable 34841-39-9, 34911-55-2 444
25
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
26
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
27
Cyproheptadine Approved Phase 4 129-03-3 2913
28
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 75614-87-8, 51-45-6 774
29
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
30
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
31
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 112111-43-0
32
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
33
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
34
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
35
Oxcarbazepine Approved Phase 4 28721-07-5 34312
36
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
37
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
38
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73-31-4 896
39 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Not Applicable
40
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 1406-16-2
41
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 1406-66-2 14986
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-02-9 14985
43
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 56-86-0 33032
44
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
45 Etiracetam Investigational Phase 4 33996-58-6
46 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1193)
# Name Status NCT ID Phase Drugs
1 Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties Unknown status NCT01393574 Phase 4 Melatonin;Methylphenidate
2 Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers Unknown status NCT02623114 Phase 4 methylphenidate;atomoxetine
3 International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder Unknown status NCT00863499 Phase 4 Short Acting Methylphenidate;Long Acting Methylphenidate
4 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
5 Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD Unknown status NCT02074228 Phase 4 Methylphenidate (Concerta)
6 Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD) Unknown status NCT00862108 Phase 4 Methylphenidate
7 Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
8 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
9 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
10 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
11 A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
12 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
13 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
14 Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Unknown status NCT00252278 Phase 4 atomoxetine
15 Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules
16 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
17 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
18 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
19 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
20 Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder Completed NCT01439126 Phase 4 clonidine hydrochloride;Placebo
21 Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children Completed NCT00754208 Phase 4 methylphenidate
22 A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants Completed NCT01933880 Phase 4 Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
23 Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children Completed NCT01065259 Phase 4 OROS MPH;Atomoxetine
24 Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00783835 Phase 4 Long-Acting Methylphenidate
25 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. Completed NCT01873729 Phase 4 Naltrexone
26 Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01238822 Phase 4 Methylphenidate;placebo;Methylphenidate;Methylphenidate
27 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4 Atomoxetine
28 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
29 Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder Completed NCT00866996 Phase 4 Methylphenidate extended-release; Atomoxetine
30 A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder Completed NCT00518232 Phase 4 OROS-methylphenidate
31 Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder Completed NCT01831622 Phase 4 Ritalin;Placebo
32 Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD) Completed NCT00842127 Phase 4 OROS-methylphenidate (Concerta)
33 A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Completed NCT00471354 Phase 4 Atomoxetine
34 Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults Completed NCT00753012 Phase 4 Lisdexamfetamine
35 An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01012622 Phase 4 Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
36 Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00937040 Phase 4 OROS MPH;Placebo;OROS MPH Tablets;Placebo Tablets
37 An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT01060150 Phase 4 OROS Methylphenidate HCl
38 Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse) Completed NCT01070394 Phase 4 LDX Treatment
39 Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00856063 Phase 4 atomoxetine (or placebo)
40 Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01069523 Phase 4 Guanfacine Extended Release;Placebo
41 Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00546910 Phase 4 Atomoxetine;Placebo
42 Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder Completed NCT00429273 Phase 4 Guanfacine;Methylphenidate (MPH)
43 Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder Completed NCT01552915 Phase 4 Lisdexamfetamine dimesylate;Methylphenidate Hydrochloride;Placebo
44 Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder Completed NCT01552902 Phase 4 Lisdexamfetamine dimesylate;Methylphenidate Hydrochloride;Placebo
45 Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
46 The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00758160 Phase 4 OROS Methylphenidate
47 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
48 Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD Completed NCT00585910 Phase 4 Atomoxetine and OROS Methylphenidate
49 Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children Completed NCT00254462 Phase 4 Atomoxetine;Placebo
50 Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder) Completed NCT00221962 Phase 4 Aripiprazole

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: attention deficit disorder with hyperactivity

Genetic Tests for Attention Deficit-Hyperactivity Disorder

Genetic tests related to Attention Deficit-Hyperactivity Disorder:

# Genetic test Affiliating Genes
1 Attention Deficit Hyperactivity Disorder 29 DRD4 DRD5

Anatomical Context for Attention Deficit-Hyperactivity Disorder

MalaCards organs/tissues related to Attention Deficit-Hyperactivity Disorder:

41
Brain, Testes, Thyroid, Eye, Cortex, Liver, Breast

Publications for Attention Deficit-Hyperactivity Disorder

Articles related to Attention Deficit-Hyperactivity Disorder:

(show top 50) (show all 2238)
# Title Authors Year
1
Quality of life and psychosocial functioning in adolescents with developmental coordination disorder and attention-deficit-hyperactivity disorder. ( 29727010 )
2018
2
Hippocampal subfield volume changes in subtypes of Attention Deficit Hyperactivity Disorder. ( 29427578 )
2018
3
Interpretation of ambiguous facial affect in adults with attention-deficit/hyperactivity disorder. ( 29423564 )
2018
4
Does the efficacy of parent-child training depend on maternal symptom improvement? Results from a randomized controlled trial on children and mothers both affected by attention-deficit/hyperactivity disorder (ADHD). ( 29362929 )
2018
5
The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. ( 29847836 )
2018
6
A cross-sectional study of the relationship between infant Thimerosal-containing hepatitis B vaccine exposure and attention-deficit/hyperactivity disorder. ( 29413097 )
2018
7
The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. ( 29958238 )
2018
8
Attention profiles in childhood absence epilepsy compared with attention-deficit/hyperactivity disorder. ( 28992996 )
2018
9
Do Signs of Attention-Deficit/Hyperactivity Disorder Increase the Odds of Dental Caries? A Case-Control Study. ( 29393165 )
2018
10
Treating a Child With Anxiety and Attention-Deficit/Hyperactivity Disorder? Don't Rule Out Cognitive-Behavioral Therapy. ( 29960689 )
2018
11
Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis. ( 29269187 )
2018
12
Vitamin D Status and Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Observational Studies. ( 29438455 )
2018
13
Health-related quality of life and peer relationships in adolescents with developmental coordination disorder and attention-deficit-hyperactivity disorder. ( 29611868 )
2018
14
Risk of Traumatic Brain Injury Among Children, Adolescents, and Young Adults With Attention-Deficit Hyperactivity Disorder in Taiwan. ( 29970331 )
2018
15
Exploring the Effects of Working Memory on Time Perception in Attention Deficit Hyperactivity Disorder. ( 29417882 )
2018
16
Orbitofrontal Signaling of Future Reward is Associated with Hyperactivity in Attention-Deficit/Hyperactivity Disorder. ( 29954849 )
2018
17
Attention-deficit/hyperactivity disorder, joint hypermobility-related disorders and pain: expanding body-mind connections to the developmental age. ( 29446032 )
2018
18
The interactions among organophosphate pesticide exposure, oxidative stress, and genetic polymorphisms of dopamine receptor D4 increase the risk of attention deficit/hyperactivity disorder in children. ( 29054088 )
2018
19
Working Memory and Motor Activity: A Comparison Across Attention-Deficit/Hyperactivity Disorder, Generalized Anxiety Disorder, and Healthy Control Groups. ( 29704970 )
2018
20
Atomoxetine in the Treatment of Adolescent With Trichotillomania and Attention-Deficit/Hyperactivity Disorder. ( 29533364 )
2018
21
Attention-deficit hyperactivity disorder in Brazilian patients with phenylketonuria. ( 29981005 )
2018
22
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. ( 29944175 )
2018
23
Risk of subsequent attention-deficit/hyperactivity disorder among children and adolescents with amalgam restorations: A nationwide longitudinal study. ( 28782290 )
2018
24
Risk factors influencing severity of attention deficit hyperactivity disorder in a sample of preparatory school students in Cairo. ( 29451009 )
2018
25
Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. ( 29121517 )
2018
26
Altered patterns of resting-state functional connectivity between the caudate and other brain regions in medication-naA^ve children with attention deficit hyperactivity disorder. ( 28863310 )
2018
27
Sudden infant death syndrome, attention-deficit/hyperactivity disorder and vaccines: Longitudinal population analyses. ( 29289380 )
2018
28
Errors on a computer task and subclinical symptoms of attention-deficit/hyperactivity disorder (ADHD). ( 29971801 )
2018
29
Predicting Clinical Gains and Side Effects of Stimulant Medication in Pediatric Attention-Deficit/Hyperactivity Disorder by Combining Measures From qEEG and ERPs in a Cued GO/NOGO Task. ( 29940782 )
2018
30
Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. ( 29422022 )
2018
31
Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release. ( 29422931 )
2018
32
Difficulties faced by university students with self-reported symptoms of attention-deficit hyperactivity disorder: a qualitative study. ( 29434656 )
2018
33
Outpatient rehabilitation resources and medical expenditure in children with attention-deficit hyperactivity disorder in Taiwan. ( 29953532 )
2018
34
Implicit sequence learning in young people with Tourette syndrome with and without co-occurring attention-deficit/hyperactivity disorder. ( 29972622 )
2018
35
Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review. ( 29940719 )
2018
36
Attention deficit hyperactivity disorder and autism spectrum disorder symptoms in school-age children born very preterm. ( 29413425 )
2018
37
Junior temperament character inventory together with quantitative EEG discriminate children with attention deficit hyperactivity disorder combined subtype from children with attention deficit hyperactivity disorder combined subtype plus oppositional defiant disorder. ( 29787785 )
2018
38
Association of Gestational Age at Birth With Symptoms of Attention-Deficit/Hyperactivity Disorder in Children. ( 29946656 )
2018
39
Association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS). ( 29961556 )
2018
40
Evaluation of motor proficiency and adiponectin in adolescent students with attention deficit hyperactivity disorder after high-intensity intermittent training. ( 29276993 )
2018
41
Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation. ( 29411149 )
2018
42
Sex-specific manifestation of genetic risk for attention deficit hyperactivity disorder in the general population. ( 29451303 )
2018
43
Maternal Biomarkers of Acetaminophen Use and Offspring Attention Deficit Hyperactivity Disorder. ( 29970852 )
2018
44
Associations between urinary cotinine and symptoms of attention deficit/hyperactivity disorder and autism spectrum disorder. ( 29957501 )
2018
45
The Pharmacology of Amphetamine and Methylphenidate: Relevance to the Neurobiology of Attention-Deficit/Hyperactivity Disorder and Other Psychiatric Comorbidities. ( 29428394 )
2018
46
The Short-Term Placebo Response in Children With Attention-Deficit Hyperactivity Disorder (ADHD). ( 29451082 )
2018
47
A Review of Childhood Behavioral Problems and Disorders in the Development of Obesity: Attention Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, and Beyond. ( 29411333 )
2018
48
Early developmental pathways to childhood symptoms of attention-deficit hyperactivity disorder, anxiety and autism spectrum disorder. ( 29963709 )
2018
49
Attention deficit-hyperactivity disorder is associated with allergic symptoms and low levels of hemoglobin and serotonin. ( 29980754 )
2018
50
Association between attention-deficit/hyperactivity disorder and amyotrophic lateral sclerosis. ( 29958655 )
2018

Variations for Attention Deficit-Hyperactivity Disorder

ClinVar genetic disease variations for Attention Deficit-Hyperactivity Disorder:

6
(show all 50)
# Gene Variation Type Significance SNP ID Assembly Location
1 DRD5 DRD5, (CA)n MARKER undetermined variant risk factor
2 DRD4 DRD4, 120-BP INS insertion risk factor
3 VPS13B NM_017890.4(VPS13B): c.1219C> T (p.Gln407Ter) single nucleotide variant Pathogenic rs386834070 GRCh37 Chromosome 8, 100146872: 100146872
4 VPS13B NM_017890.4(VPS13B): c.1219C> T (p.Gln407Ter) single nucleotide variant Pathogenic rs386834070 GRCh38 Chromosome 8, 99134644: 99134644
5 C12orf4 NM_020374.3(C12orf4): c.639_640insACAA (p.Gln214Thrfs) insertion Likely pathogenic rs730882197 GRCh38 Chromosome 12, 4525342: 4525343
6 C12orf4 NM_020374.3(C12orf4): c.639_640insACAA (p.Gln214Thrfs) insertion Likely pathogenic rs730882197 GRCh37 Chromosome 12, 4634508: 4634509
7 CHAF1B NM_005441.2(CHAF1B): c.496A> G (p.Ile166Val) single nucleotide variant Likely pathogenic rs140630794 GRCh38 Chromosome 21, 36397429: 36397429
8 CHAF1B NM_005441.2(CHAF1B): c.496A> G (p.Ile166Val) single nucleotide variant Likely pathogenic rs140630794 GRCh37 Chromosome 21, 37769727: 37769727
9 MECP2 NM_001110792.1(MECP2) indel Pathogenic rs786205019 GRCh38 Chromosome X, 154030644: 154030664
10 MECP2 NM_001110792.1(MECP2) indel Pathogenic rs786205019 GRCh37 Chromosome X, 153296095: 153296115
11 KIF5B NM_004521.2(KIF5B): c.2252A> G (p.His751Arg) single nucleotide variant Likely pathogenic rs1114167297 GRCh38 Chromosome 10, 32019912: 32019912
12 KIF5B NM_004521.2(KIF5B): c.2252A> G (p.His751Arg) single nucleotide variant Likely pathogenic rs1114167297 GRCh37 Chromosome 10, 32308840: 32308840
13 C12orf57 NM_138425.3(C12orf57): c.53-2A> G single nucleotide variant Pathogenic rs1114167293 GRCh37 Chromosome 12, 7053637: 7053637
14 C12orf57 NM_138425.3(C12orf57): c.53-2A> G single nucleotide variant Pathogenic rs1114167293 GRCh38 Chromosome 12, 6944474: 6944474
15 TMEM47 NM_031442.3(TMEM47): c.35G> C (p.Arg12Pro) single nucleotide variant Likely pathogenic rs1114167296 GRCh37 Chromosome X, 34675112: 34675112
16 TMEM47 NM_031442.3(TMEM47): c.35G> C (p.Arg12Pro) single nucleotide variant Likely pathogenic rs1114167296 GRCh38 Chromosome X, 34656995: 34656995
17 MAGED2 NM_201222.2(MAGED2): c.1003delC (p.Gln335Asnfs) deletion Likely pathogenic rs1114167295 GRCh38 Chromosome X, 54812169: 54812169
18 MAGED2 NM_201222.2(MAGED2): c.1003delC (p.Gln335Asnfs) deletion Likely pathogenic rs1114167295 GRCh37 Chromosome X, 54838602: 54838602
19 GNB5 NM_006578.3(GNB5): c.242C> T (p.Ser81Leu) single nucleotide variant Pathogenic rs761399728 GRCh37 Chromosome 15, 52446144: 52446144
20 GNB5 NM_006578.3(GNB5): c.242C> T (p.Ser81Leu) single nucleotide variant Pathogenic rs761399728 GRCh38 Chromosome 15, 52153947: 52153947
21 46;XY;t(4;14)(p15.32;q32.1)dn Translocation Uncertain significance
22 46;XY;t(6;11)(q23;q21)or(q25;q21)dn Translocation Uncertain significance
23 Translocation Likely pathogenic
24 46;XX;t(9;19)(q22.3;q13.1)dn Translocation Uncertain significance
25 46;XY;t(8;10)(q13;p13)dn Translocation Pathogenic
26 46;XY;t(1;3)(p22;q21)dn Translocation Uncertain significance
27 46;XY;t(2;11)(q31;q13.5)pat Translocation Uncertain significance
28 46;XX;t(10;14)(p13;q21)dn Translocation Likely pathogenic
29 46;XX;inv(7)(q11.23q36.3)dn inversion Pathogenic
30 46;XY;t(20;22)(q13.3;q11.2) Translocation Uncertain significance
31 46;XY;t(3;5)(q24;p15.3)dn Translocation Pathogenic
32 46;XY;t(4;7)(q31;q22)dn Translocation Uncertain significance
33 46;XY;t(12;14)(q15;q13)mat Translocation Uncertain significance
34 46;XY;t(5;15)(q11.2;q24) Translocation Pathogenic
35 46;XY;inv(2)(q11.2q24.2)dn inversion Uncertain significance
36 46;XX;t(2;5)(q33;p15.3) Translocation Uncertain significance
37 46;X;inv(X)(q27q28) inversion Uncertain significance
38 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic
39 DEAF1 NM_021008.3(DEAF1): c.667G> A (p.Gly223Ser) single nucleotide variant Uncertain significance rs1057518811 GRCh37 Chromosome 11, 686995: 686995
40 DEAF1 NM_021008.3(DEAF1): c.667G> A (p.Gly223Ser) single nucleotide variant Uncertain significance rs1057518811 GRCh38 Chromosome 11, 686995: 686995
41 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh37 Chromosome 6, 12124117: 12124117
42 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh38 Chromosome 6, 12123884: 12123884
43 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh37 Chromosome 9, 90584834: 90584834
44 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh38 Chromosome 9, 87969919: 87969919
45 SCAPER NM_020843.2(SCAPER): c.2973_2976delCAAT (p.Ile991Metfs) deletion Pathogenic GRCh38 Chromosome 15, 76471314: 76471317
46 SCAPER NM_020843.2(SCAPER): c.2973_2976delCAAT (p.Ile991Metfs) deletion Pathogenic GRCh37 Chromosome 15, 76763655: 76763658
47 CDRT4; HS3ST3B1; PMP22; TEKT3; TVP23C; TVP23C-CDRT4 GRCh37/hg19 17p12(chr17: 14215739-15422582) copy number loss Pathogenic GRCh37 Chromosome 17, 14215739: 15422582
48 CDRT4; HS3ST3B1; PMP22; TEKT3; TVP23C; TVP23C-CDRT4 GRCh37/hg19 17p12(chr17: 14215739-15422582) copy number loss Pathogenic GRCh37 Chromosome 17, 14215739: 15422582
49 subset of 47 genes:TBX1 GRCh37/hg19 22q11.21(chr22: 18894835-21505417) copy number loss Pathogenic GRCh37 Chromosome 22, 18894835: 21505417
50 covers 13 genes, none of which curated to show dosage sensitivity GRCh37/hg19 3q29(chr3: 195457650-196263123) copy number loss Uncertain significance GRCh37 Chromosome 3, 195457650: 196263123

Copy number variations for Attention Deficit-Hyperactivity Disorder from CNVD:

7 (show top 50) (show all 84)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 34465 1 56053497 56064495 Deletion USP24 Attention deficit hyperactivity disorder
2 34466 1 56053497 56064495 Deletion USP24e Attention deficit hyperactivity disorder
3 36125 1 72317292 72328395 Duplication NEGR1 Attention deficit hyperactivity disorder
4 49516 11 107520009 107885084 Duplication C11orf65 Attention deficit hyperactivity disorder
5 49517 11 107520009 107885084 Duplication EXPH5 Attention deficit hyperactivity disorder
6 49518 11 107520009 107885084 Duplication KDELC2 Attention deficit hyperactivity disorder
7 60337 11 85300000 92300000 Deletion GRM5 Attention deficit hyperactivity disorder
8 60583 11 88269449 88351661 Deletion GRM5 Attention deficit hyperactivity disorder
9 60585 11 88269449 88351661 Het ACAT1 Attention deficit hyperactivity disorder
10 60586 11 88269449 88351661 Het ATM Attention deficit hyperactivity disorder
11 60587 11 88269449 88351661 Het GRM5 Attention deficit hyperactivity disorder
12 60588 11 88269449 88351661 Het NPAT Attention deficit hyperactivity disorder
13 63163 12 115300000 116700000 Duplicated NOS1 Attention deficit hyperactivity disorder
14 69603 12 55902280 55923860 Deletion NDUFA4L2 Attention deficit hyperactivity disorder
15 69604 12 55902280 55923860 Deletion NXPH4 Attention deficit hyperactivity disorder
16 69605 12 55902280 55923860 Deletion SHMT2 Attention deficit hyperactivity disorder
17 69606 12 55902280 55923860 Deletion STAC3 Attention deficit hyperactivity disorder
18 75846 13 24844208 25493420 Duplication or delet ion ATP8A2 Attention deficit hyperactivity disorder
19 76965 13 38815028 39075356 Duplication or delet ion LHFP Attention deficit hyperactivity disorder
20 78033 13 48967801 49001118 Duplication or delet ion PHF11 Attention deficit hyperactivity disorder
21 78043 13 49004082 49057720 Duplication or delet ion RCBTB1 Attention deficit hyperactivity disorder
22 79472 13 72254230 72488592 Duplication or delet ion PIBF1 Attention deficit hyperactivity disorder
23 91412 15 30110017 30248527 Deletion CHRNA7 Attention deficit hyperactivity disorder
24 99563 16 27600000 34400000 Deleted ERK1 Attention deficit hyperactivity disorder
25 99685 16 28100000 34600000 Deletion CORO1A Attention deficit hyperactivity disorder
26 101713 16 45500000 51200000 Duplicated ZNF423 Attention deficit hyperactivity disorder
27 103489 16 6072599 6783832 Duplication A2BP1 Attention deficit hyperactivity disorder
28 106366 16 87694595 87778383 Deletion CDH15 Attention deficit hyperactivity disorder
29 109330 17 25613604 26191779 Duplication BLMH Attention deficit hyperactivity disorder
30 117083 17 71112486 71120734 Deletion Attention deficit hyperactivity disorder
31 122044 18 52000000 54400000 Duplicated NEDD4L Attention deficit hyperactivity disorder
32 123018 18 65358832 65367619 Deletion DOK6 Attention deficit hyperactivity disorder
33 125924 19 15992679 15997923 Deletion LOC126536 Attention deficit hyperactivity disorder
34 127980 19 38427720 38444834 Deletion SLC7A10 Attention deficit hyperactivity disorder
35 127981 19 38427720 38444834 Deletion SLC7A10e Attention deficit hyperactivity disorder
36 132645 19 59423491 59428132 Duplication LILRB3 Attention deficit hyperactivity disorder
37 132646 19 59423491 59428132 Duplication LIR-3 Attention deficit hyperactivity disorder
38 136696 2 132200000 134800000 Deleted NAP5 Attention deficit hyperactivity disorder
39 139372 2 1792886 2335045 Duplication or delet ion MYT1L Attention deficit hyperactivity disorder
40 146272 2 47600000 52700000 Deleted NRXN1 Attention deficit hyperactivity disorder
41 146517 2 50145643 51259674 Duplication or delet ion NRXN1 Attention deficit hyperactivity disorder
42 146826 2 55088956 55239201 Duplication RTN4 Attention deficit hyperactivity disorder
43 148301 2 75400000 83700000 Deleted CTNNA2 Attention deficit hyperactivity disorder
44 148598 2 81419297 81446082 Duplication CTNNA2 Attention deficit hyperactivity disorder
45 148599 2 81419297 81446082 Duplication CTNNA2e Attention deficit hyperactivity disorder
46 154924 20 5000000 9000000 Deleted BMP2 Attention deficit hyperactivity disorder
47 164095 22 34870070 34916870 Het APOL3 Attention deficit hyperactivity disorder
48 164096 22 34870070 34916870 Het APOL4 Attention deficit hyperactivity disorder
49 164674 22 38384374 38403731 Deletion CACNA1I Attention deficit hyperactivity disorder
50 166998 3 111722434 117006477 Deletion Attention deficit hyperactivity disorder

Expression for Attention Deficit-Hyperactivity Disorder

Search GEO for disease gene expression data for Attention Deficit-Hyperactivity Disorder.

Pathways for Attention Deficit-Hyperactivity Disorder

Pathways related to Attention Deficit-Hyperactivity Disorder according to KEGG:

37
# Name Kegg Source Accession
1 Dopaminergic synapse hsa04728
2 Serotonergic synapse hsa04726

GO Terms for Attention Deficit-Hyperactivity Disorder

Biological processes related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to amphetamine GO:0001975 9.48 DRD4 DRD5
2 response to pain GO:0048265 9.46 COMT SLC6A2
3 dopamine metabolic process GO:0042417 9.43 COMT DRD4
4 negative regulation of voltage-gated calcium channel activity GO:1901386 9.4 DRD4 GNB5
5 regulation of dopamine metabolic process GO:0042053 9.37 DRD4 SLC6A3
6 learning GO:0007612 9.33 COMT DRD5 MECP2
7 monoamine transport GO:0015844 9.32 SLC6A2 SLC6A3
8 dopamine catabolic process GO:0042420 9.26 COMT SLC6A3
9 dopamine uptake involved in synaptic transmission GO:0051583 8.96 SLC6A2 SLC6A3
10 dopamine receptor signaling pathway GO:0007212 8.8 DRD4 DRD5 GNB5

Molecular functions related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.73 ADRA2A DRD4 DRD5 GNB5
2 neurotransmitter:sodium symporter activity GO:0005328 9.4 SLC6A2 SLC6A3
3 epinephrine binding GO:0051379 9.37 ADRA2A DRD4
4 monoamine transmembrane transporter activity GO:0008504 9.32 SLC6A2 SLC6A3
5 norepinephrine binding GO:0051380 9.26 ADRA2A DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD4 DRD5
7 dopamine:sodium symporter activity GO:0005330 8.96 SLC6A2 SLC6A3
8 dopamine binding GO:0035240 8.8 DRD4 DRD5 SLC6A3

Sources for Attention Deficit-Hyperactivity Disorder

3 CDC
7 CNVD
9 Cosmic
10 <